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Abstract
Cardiovascular disease, osteoporosis, and dementia are
three disease processes that have been directly linked to
estrogen deficiency. Cardiovascular disease

(CVD) is the

number one cause of death for all postmenopausal women,
including those with end-stage renal disease

(ESRD).

Osteoporosis and dementia are disease processes that
profoundly affect the quality of life for postmenopausal
women.

Currently,

34% of women in the general population

receive hormone replacement therapy (HRT), while only 10%
of women with ESRD receive this therapy. Therefore, the
purpose of this descriptive study was to examine the
facilitators and barriers of nephrology health care
providers to initiation of HRT among their postmenopausal
patients.

Pender's Health Promotion Model was utilized for

the theoretical framework. The research questions that
guided the study were as follows: What are the barriers to
nephrology health care providers initiating HRT on
postmenopausal women with ESRD? And what are the
facilitators to nephrology health care providers
initiating HRT on postmenopausal women with ESRD? The
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target population was nephrology health care providers at
outpatient hemodialysis facilities. Tramel's Questionnaire
was utilized to collect data. The convenience sample

(N =

2 6) consisted of subjects who completed and returned the
questionnaire for a 17% return.

Descriptive statistics,

including frequency distribution, percentage,
were utilized to analyze the data.
providers were 80.77%

and ranking,

Nephrology health care

(n — 21) male and practiced

nephrology for an average 12.8 years. The average number
of postmenopausal women under their care was 138, and
42.31%

(n = 11) reported prescribing HRT for these women.

The number one ranked health facilitator to prescribing
HRT was surgically-induced menopause. The need for more
research in the area of HRT for women with renal failure
was the number one ranked external facilitator. The number
one ranked barrier to HRT initiation was a concern of
physician liability. One implication for nursing is the
need for continued research in the area of menopause for
women with ESRD. Recommendations for further research
included replication of this study with expanded
geographical area and continued use of the research tool
to establish reliability and validity.
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the name of the Lord Jesus, giving thanks to God
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I dedicate this thesis as well as my life and work to
Jesus Christ,
His Will

my Lord and Savior,

for I know that it is

that I work with patients who have renal failure.

For I was an hungred, and ye gave me no meat: I
was thirsty, and ye gave me no drink: I was a
stranger, and ye took me not in: naked, and ye
clothed me not: sick, and in prison, and ye
visited me not.
Then shall they also answer
him, saying. Lord, when saw we thee an hungred,
or athirst, or a stranger, or naked, or sick, or
in prison, and did not minister unto thee? Then
shall he answer them saying. Verily I say unto
you. Inasmuch as ye did it not to one of the
least of these, ye did it not to me.
Matthew
25:42-45
Many dialysis patients are indigent; some have poor
hygiene and very little clothing. Many rely on social
services for transportation to and from hospitals and
dialysis, doctor's appointments, the grocery store, and
other personal business.

Imagine having a stranger pick

you up and take you home after a 2-week stay in the
hospital. Often the only support they receive after
getting home is a home health nurse

(if they are lucky

enough to qualify for this service) and one hot meal per
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day from "Meals on Wheels".

For many dialysis patients the

highlight of their week is coming to dialysis,

for it may

be the only socialization they receive; the only time
someone touches them or speaks kindly to them. Being poor
is a great trial in itself, as are the problems of living
day to day with kidney failure. Coping with daily needs is
enough, and often too much, without others looking down on
you, especially health care providers.

I became a nurse

because I wanted to provide comfort and care for those in
need.

I vowed many years ago to care for my patients just

as I would want my loved ones cared for.
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others, but if there is no real caring for that person,
then it is done to benefit ourselves in some way. Most
people are like children; they know when you truly care
and when you don't. Romans 13:8 says our first
responsibility is to love : "Owe no man anything, but to
love one another . . ."
This thesis is also dedicated to someone very special
to me, my brother,

David.

I love you very much.
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Chapter I
The Research Problem
A renewed interest in women's health care issues over
the past several years has facilitated research about
menopause and the use of estrogen. Many clinical trials
have confirmed the benefits of hormone replacement therapy
to postmenopausal women.

Some of these benefits included

relief of menopausal symptoms,

reduction in the risk of

osteoporosis, maintenance of bone mass,

improvement in

lipid profiles and cognitive function, and reduction in
the risk of cardiovascular morbidity and mortality
Schmidt, Bender,

Dumler,

& Schiff,

1997).

(Holly,

In addition,

recent studies have shown that the use of hormone
replacement therapy

(HRT) can prevent, lessen the severity

of, or reverse dementia, particularly Alzheimer's disease
(Brinton,

1997).

Although the average age for women to be in a state
of menopause has remained unchanged at 51.4 years,

life

expectancy has increased. By the year 2003, a woman can
expect to live an average of 80 years; today women may
live one third to one half of their lives past menopause
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in an estrogen deficient state

(Lobo, 1999). Because of

the benefits of HRT, its use in the general population has
increased during the past 20 years. Currently,

34% of

postmenopausal women in the United States are prescribed
HRT. Within this population only 10% of postmenopausal
women with end-stage renal disease

(ESRD) receive a

prescription for HRT from their health care provider even
though the mean age for menopause is decreased to 47 years
in these patients

(Holly et al., 1997).

The population of postmenopausal women in the United
States is climbing at an exponential rate. In 1990 there
were 28.7 million women older than 55 years of age; by the
year 2020 this group is estimated to be 45.9 million.

In

1999 over 31 million women began the menopausal transition
(Lobo,

1999). As the general population ages, the number

of postmenopausal women with ESRD also will increase. The
prevalence rate for ESRD among postmenopausal women was
607 per million in 1991 and had climbed to 931 per million
in 1997

(Mattix & Singh, 2000). Cardiovascular disease

(CVD), osteoporosis,

and dementia are three disease

processes that profoundly affect the quality of life and
health of ESRD patients who are menopausal

(D. Arnold,

personal communication. May 14, 2001). Nephrology health
care providers have ignored the issue of HRT in their
postmenopausal patients despite mounting evidence that
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estrogen therapy could possibly decrease morbidity and
mortality and positively influence quality of life
& Singh, 2000).

(Mattix

In an effort to better understand the

disparity of HRT prescription in women with ESRD, this
researcher explored the prescription practices of
nephrology health care providers regarding initiation of
HRT.
The American Association of Clinical Endocrinologist
(AACE) has cited the following primary goals for HRT:
relief of menopausal symptoms and prevention of
cardiovascular disease, osteoporosis,

and dementia.

Some

common menopause related symptoms that are relieved by HRT
are hot flashes, decreased libido, depression,
insomnia, mood swings, nervousness, myalgia,

headache,

and

formications. Therapeutic levels of estrogen decrease the
risk of cardiovascular disease, osteoporosis,
cognitive dysfunction

and

("Managing Menopause," 2000).

Sufficient data exist to suggest that all-cause mortality
is decreased in women who take HRT, mainly because of the
decrease in heart disease

(Lobo, 1999). The AACE has

recommended that all postmenopausal women consider HRT as
preventive medicine

("Managing Menopause," 2000). Existing

research data and the AACE's position are considered
facilitating factors for initiating HRT for women by
health care providers.
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Cardiovascular disease is the number one cause of
death in all postmenopausal women and the number one cause
of morbidity and mortality in women with ESRD.
"Cardiovascular disease in ESRD patients has reached
epidemic proportions"

(Mattix & Singh, 2000, p. 207).

From

1995 to 1997 CVD accounted for more than 80% of deaths in
ESRD patients over the age of 65 and 42% of all deaths in
women age 45 to 64 years. The risk for CVD is increased
threefold for women after menopause, thus menopause may be
related to this high rate of death due to CVD in women
with ESRD

(Mattix & Singh, 2000). After menopause, women

experience an accelerated rate of cardiovascular events,
as well as a decrease in high-density lipoproteins
and an increase in low-density lipoproteins

(HDL)

(LDL).

Numerous studies have evaluated the effect of HRT on
cardiovascular function.

In 1997 Grodstein,

Stampfer,

and

Coldita determined that after 15 years of estrogen
replacement,

risk of death by cardiovascular disease

(CVD)

was reduced by nearly 50%, and overall death was reduced
by 40%. Some researchers credit these positive
cardiovascular effects on the ability of estrogen to
maintain lipoproteins at healthier levels through its
interaction with proteins in the liver

(Ginsburg et al.,

1998) . Other researchers believe that estrogen has a
direct effect on blood vessels by reacting with receptors
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on the vessel walls
al.

(1998)

(Women's Health,

2000). Ginsburg et

found that women with ESRD and coronary artery

stenosis who received estrogen replacement at any time had
a decrease in risk of death up to 27%.
HRT has been a preventative measure for the
development of osteoporosis,

a condition in which bones

become thin, fragile, and fracture easily as a result of
low bone mass. The decline in bone mass that occurs with
estrogen deficiency is caused by osteoclastic activity
(increased resorption)
osteoblastic activity

which becomes uncoupled from
(bone formation). The deficiency

also has an indirect effect on parathyroid hormone and
cytokines, which oppose the resorptive effects. The
positive effects of estrogen on growth factors,
calcitonin, vitamin D metabolism,

and calcium absorption

also are diminished in estrogen deficient women

(Lobo,

1999).
As a result of an estrogen deficiency, and at an
annual cost of $10 billion, approximately 800,000 U.S.
women fracture a vertebrae or hip, and an estimated 12% to
20% of these women do not survive the 6 months following
the fracture. In a 1995 study, Lyhne and Pedersen
evaluated the treatment of renal osteodystrophy in 23
dialysis patients. The researchers found that women
demonstrated a significant decrease in bone mineral

6

content as compared to men. The bone mineral content
decrease for females was 6% per year, but was
insignificant for males in the study. Comparable findings
in the general population have shown that bone mineral
content decreases 1% per year in females 35 to 65 years of
age and 2% per year in perimenopause

(Lyhne & Pedersen,

1995). The significant difference in female bone mineral
content suggests severe skeletal imbalances and could be
related to sex hormone imbalances. The U.S. Food and Drug
Administration

(FDA) has approved the use of estrogen for

the prevention of osteoporosis which currently is the most
effective therapy for the prevention and treatment of
osteoporosis

(Women's Health, 2000).

Although the life expectancy of women is greater than
men, women suffer greater negative consequences of the
aging process than men. One such consequence is dementia,
particularly Alzheimer's disease. In a 1996 study, Birge
found that women were three times more likely to develop
dementia than men, and women with CVD were five times more
likely to develop dementia than women with no CVD. These
data show that women have a higher risk for developing
dementia than men and that a medical insult,
myocardial infarction,

such as

stroke, or renal failure, may

exacerbate dementia in women

(Brinton,

1997).
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Past authors on aging and dementia have shown that
estrogen positively affects cognitive function; however,
recent authors have produced evidence that estrogen delays
the onset and progression of Alzheimer's disease.

Five

epidemiologic studies conducted from 1994 to 1996
demonstrated a 4 0% to 60% reduction in the risk of
Alzheimer's disease in women who had taken HRT

(Hammond,

1999). Women treated with estrogen demonstrated a
significant memory improvement and delay in cognitive
loss. For example, in 1996 Tang et al. conducted a study
of 1,124 women who were followed from 1 to 5 years. The
study demonstrated that women who took estrogen for one
year had a dramatic delay in the onset of Alzheimer's
disease. The researchers also determined that women who
only briefly took HRT for menopausal symptom control
experienced this delay in onset. Thus, it is speculated
that even brief exposure to estrogen prevents irreversible
loss of neurons and thereby influences the expression of
Alzheimer's disease

(up to 30 years later). Recent studies

have shown that estrogen stimulates the expression of
neurotrophic factors, protects neurons from toxicity,
stimulates axonal regeneration,

and stimulates the

production of acetylcholine and serotonin

(Hammond,

1999).

Early studies on the reproductive function of female
dialysis patients found the majority of these women to be
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amenorrheic with no ovarian function. Results of studies
conducted in the 1980s were that only 10% of premenopausal
women had regular menses, but few studies have been done
since 1987, when erythropoietin was introduced to the ESRD
community. Erythropoietin is a hormone produced by the
kidney to stimulate production of red blood cells;
patients with ESRD were severely anemic prior to its
introduction in 1987

(D. Arnold, personal correspondence.

May 10, 2001). The etiology of ovarian failure is poorly
understood but is thought to be hypothalamic in origin and
possibly related to the elevated levels of prolactin
associated with renal failure.

In 1997, Holly et al.

conducted a study of 7 6 premenopausal women receiving
dialysis at four outpatient dialysis facilities in the
United States. The researchers' purpose was to identify
menstrual patterns,

contraception,

HRT use, and sexuality

issues. Women age 55 years and older when beginning
dialysis were excluded from the study. Contrasted to
earlier reports that only 10% of premenopausal dialysis
patients menstruate regularly, Holley et al. found 42%
=32)

of the subjects had regular periods. The sample

(59%, n = 45) of women with ESRD also reported having
irregular periods,

and 64%

(14 of 22) of the subjects

reported heavy menstrual flow with clots. Of the sample

(n

9

(N = 76), 19 were postmenopausal. Of these,

5 reported

menopause occurring after starting dialysis.
In the same year, Cochrane and Regan

(1997) undertook

a prospective study to establish the nature and extent of
gynecological disorders among 100 women with ESRD,
including transplanted patients. The researchers found
that of the 62 subjects who were menstruating,
50) had menorrhagia and 35%

81%

(n =

(n = 33) were amenorrheic.

the 35 menopausal women in the study, 20%

Of

(n = 7) were

less than 40 years of age and only 2 were on HRT. A total
of 49 women enrolled in the study were less than 40 years
of age; of these,

14% had primary ovarian failure.

Prolactin levels in all subjects were normal except for
those on hemodialysis which were elevated. The researchers
concluded that 85% of these patients had menstrual
disorders, mainly menorrhagia, which was of concern
because heavy vaginal bleeding worsened the anemia of
ESRD. Of the women identified as menopausal,

all were

recommended to initiate HRT. Cochrane and Regan determined
that contraceptive counseling had been inappropriate or
nonexistent and recommended all women with ESRD seek
contraceptive counseling. Low-dose combined oral
contraceptives were prescribed for most patients which had
the added benefit of improved cyclic control. The
eightfold increase in cervical dyskariosis among sample
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women was thought to be related to the use of
immunosuppressive drugs. Of significance is the fact that
80% of these abnormalities would have been missed had the
researchers not preformed cervical smears on all patients.
Cochrane and Regan

(1997) confirmed the value of regular

gynecological surveillance for seemingly asymptomatic
women with chronic renal failure based on the unrecognized
pathology identified in the study.
Hyperprolactinaemia is frequent in women with ESRD
and associated with decreased oestadiol levels, decrease
in sexual function, and depression.

In 1999,

Matuszkiewicz-Rowinska et al. documented the benefits of
biweekly transdermal oestradine in premenopausal estrogen
deficient women on dialysis. The researchers concluded
that normalization of oestradiol levels caused a fivefold
reduction in prolactin/oestradiol ratio accompanied by an
increase in general well-being,
and physical activity

sexual function,

libido,

(Matuszkiewicz-Rowinska et al.,

1999).
The AACE,
organizations,

as well as other professional
has recommended that all postmenopausal

women consider HRT as preventive medicine. The primary
contraindications to HRT are a history of breast or
endometrial cancer,

stroke, heart attack, liver disease,

history of venous thrombosis, and undiagnosed vaginal
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bleeding. Relative risks are smoking, hypertension, benign
breast and uterine disease, endometriosis, pancreatitis,
epilepsy,

and headaches

without risks,

(Women's Health, 2000). HRT is not

including endometrial disease, breast

cancer, vaginal bleeding,

somatic complaints

tenderness), and idiosyncratic reactions,

(breast

such as

hypertension and venous thrombosis. These risks must be
weighed against the potential benefits for each individual
client on a case-by-case review

(Lobo, 1999).

The documented benefits of HRT are numerous; however,
the rate of HRT prescription remains low among women with
renal failure. The purpose of this research,

therefore,

was to identify the facilitators and barriers to HRT
prescription among these women. Possible barriers to
health care providers prescribing HRT for women with ESRD
include the perception that they are unlikely to benefit
from HRT because of chronic illness and or shortened life
span or because they may have a higher risk of adverse
effects of estrogen

(Andreoli, 2000).

physician attitude,

ethnicity,

Factors such as

secular trend, and

geographic location also could explain the overall low
rate of HRT among postmenopausal women with ESRD
Gipson,

& Stehman-Breen,

(Gillen,

1999). Another barrier to

consider might be physician's lack of knowledge concerning
HRT, such as dose and type to prescribe. Nephrologists are
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specialists and may view HRT as primary care, and they opt
not to prescribe for this reason.
of comorbid conditions,
vascular disease,

Further considerations

such as CVD, diabetes, peripheral

and clotting disorders,

also may be

barriers to initiation of HRT in postmenopausal women on
dialysis. Nephrologists are 95% male, which could be a
barrier to initiation of HRT in itself, as they simply may
never consider menopause or consider it outside their
realm of practice.

In addition, nephrologists may focus

only on correction of medical problems relevant only to
ESRD

(D. Arnold,

2001).

CFNP, personal communication. May 10,

Facilitators to HRT initiation would include

nephrology health care providers believing and practicing
in health-promoting behaviors. Their beliefs about primary
prevention and benefits to health-promoting behaviors will
impact the way they practice.

If they perceive HRT as

having prophylactic uses, they will be more likely to
prescribe.
Significance to Nursing
The documented benefits of HRT may have significance
for postmenopausal women with ESRD. The younger age for
entering menopause in this population of patients removes
the protective cardiovascular,

cognitive,

and bone mass

effects of estrogen. Women with ESRD have a higher risk
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for cognitive dysfunction,

renal osteodystrophy,

accelerated atherosclerosis, and cardiovascular disease
compared to the general population. Cardiovascular disease
accounts for nearly half of the mortality in dialysis
patients each year. The potential benefits of HRT for
women with ESRD are numerous. The cardiovascular
protective effects alone could significantly decrease
related morbidity and mortality, as well as a substantial
decrease in associated health care costs

(Gipson,

1999).

Nephrology health care providers are in a unique
position to initiate HRT as dialysis patients are seen by
physicians and nurse practitioners on a weekly basis. By
viewing HRT as preventive medicine, these health care
providers could dramatically impact related morbidity and
mortality in postmenopausal women with ESRD,

as well as

improve their quality of life by decreasing depression and
enhancing mood. Nurse practitioners are educated to assess
and treat women holistically. The nephrology nurse
practitioner could augment the care of these women not
only in the area of HRT, but also in the areas of
teaching,

counseling, and prevention, as well as

assessment and treatment.
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Theoretical Framework
Pender's Health Promotion Model was used as the
theoretical framework for this study

(1987). The Health

Promotion Model contains concepts relevant to healthpromoting behaviors with the goal of nursing to support
the achievement of optimal health for each person.

Pender

identified behaviors and mechanisms for enhancing health
called cognitive-perceptual factors. These factors include
importance,
of health.

control of, definition,
In addition,

and perceived status

self-efficacy and perceived

benefits and barriers to health-promoting behaviors are
factors that directly impact health-influencing behaviors.
Rather than let disease happen when it is avoidable,
Pender emphasized disease prevention. When health
promotion and prevention fail to prevent disease, the
priority then shifts from primary to secondary and
tertiary care

(Pender,

1987). Often an acute illness turns

into a chronic, devastating disease that could have been
prevented by early utilization of health promotion and
disease prevention concepts.
The purpose of this study was to identify the
facilitators and barriers to nephrology health care
providers initiating HRT in postmenopausal women with
ESRD. Researchers have established that HRT initiation in
postmenopausal women can prevent CVD, osteoporosis,

and
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dementia as well as numerous other benefits. Therefore,
Pender's Health Promotion Model was utilized as a guide to
investigate the health-promoting behavior for initiating
HRT among postmenopausal women with ESRD for health care
providers.

The beliefs of nephrology health care providers

about primary prevention,

importance of health, and

perceived benefits to health-promoting behaviors are
concepts from the Health Promotion Model that are
applicable to this study.
Nurse practitioners and nephrologists working with
ESRD must buy into the perceived benefits of HRT.
Endorsing this concept could make them more apt to refer,
teach,

council, and assess their postmenopausal patients

for signs of estrogen deficiency. Another concept in the
Health Promotion Model is importance of health;

if health

care providers recognize HRT as important to health, they
could be more apt to prescribe.

If they support the

benefits of HRT, this is a facilitator; if they do not, it
is a barrier.
In Pender's revised Health Promotion Model

(1996),

the term immediate competing demands and preferences
replaced the concepts of benefits and barriers. Competing
demands refer to conflicts over which the individual
(health care provider) has low control. Chronic illness
and comorbidity associated illness of ESRD patients might
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be competing demands for the initiation of HRT in this
population of patients. Breast cancer or preexisting
cardiovascular disease are contraindications to the
initiation of HRT and would therefore be considered a
competing demand (barrier). Behaviors with high personal
control refers to preferences

(facilitator). A preference

in this study would be the health care provider's belief
that HRT has prophylactic uses, such as prevention of CVD,
osteoporosis, and dementia

(Pender, 1996).

Pender ascertains that health promotion and disease
prevention should be the primary focus in health care. The
current researcher agrees and considers HRT as a health
promotion and disease prevention strategy for
postmenopausal women with ESRD.
morbidity and mortality,

In addition to reduced

initiation of HRT to women on

dialysis may significantly improve their quality of life
by decreased menopausal symptoms,
sexual function,

increased libido and

improved physical activity,

and an

enhanced sense of well-being. These are factors that are
considered to be health-enhancing

(Tomey & Alligood,

1998).
Assumptions
The assumptions of the study were as follows:
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1. Estrogen replacement is the most effective therapy
against osteoporosis.
2. HRT plays a role in decreasing the cardiovascular
related mortality of postmenopausal women.
3. Women who are postmenopausal and have ESRD would
benefit from HRT.
4. Nephrology health care providers can describe
their prescribing practices of HRT.
-5. Health-promoting behaviors among nephrology health
care providers are influenced by competing demands and
preferences.
Statement of the Problem
Currently,

only 10% of postmenopausal women with ESRD

are prescribed HRT, while 34% of women in the general
population are prescribed HRT. As HRT may contribute to
the reduction of morbidity and mortality in patients with
ESRD, the barriers and facilitators to nephrology health
care providers initiating HRT should be addressed.
Therefore, this researcher focused on the facilitators and
barriers to the initiation of HRT in postmenopausal women
with ESRD by nephrology health care providers.
Research Questions
This study addressed the following research
questions :
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1. What are the barriers cited by nephrology health
care providers to initiate HRT for postmenopausal women
with end-stage renal disease?
2. What are the facilitators cited by nephrology
health care providers to initiate HRT for postmenopausal
women with end-stage renal disease?
Definition of Terms
For the purpose of this study, the following terms
were defined for clarity of application:
1. Barriers : Theoretical: factors which obstruct or
i mpede. Operational: factors which obstruct or impede
nephrology health care providers from initiating HRT in
postmenopausal women with end-stage renal disease as
identified on Tramel's Questionnaire.
2. Nephrology health care providers: Theoretical:
physicians and nurse practitioners who care for clients
with end-stage renal disease. Operational: physicians and
nurse practitioners who care for clients with end-stage
renal disease and reside in Alabama, Mississippi,

and

Tennessee.
3. Hormone replacement therapy: Theoretical: daily
replacement of conjugated estrogen and or
medroxyprogesterone acetate

(MPA) to alleviate symptoms of

menopause or as prophylaxis for disease prevention.
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Operational: daily replacement of conjugated estrogen and
or medroxyprogesterone acetate

(MPA) to alleviate symptoms

of menopause and prophylaxis for disease prevention as
identified on Tramel's Questionnaire.
4. Postmenopausal women: Theoretical: females who
have experienced cessation of menses for more than 12
months. Operational: females who have experienced
cessation of menses for more than 12 months and have ESRD.
5. End-stage renal disease: Theoretical : a
progressive,

irreversible renal function deterioration in

which the b o d y ’s ability to maintain metabolic and fluid
and electrolyte balance fails, resulting in uremia,

and

requiring dialysis or renal transplantation. Operational:
a progressive,

irreversible renal function deterioration

which requires dialysis or renal transplantation.

This

deteriorated disease must have been diagnosed in females
for more than 6 months.
6. Facilitator: Theoretical: a factor that makes a
task easier. Operational: a factor which would make it
easier for nephrology health care providers to initiate
HRT in postmenopausal women with ESRD as identified on
Tramel's Questionnaire.
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Summary
The purpose of this study was to identify
facilitators and barriers to HRT of postmenopausal women
with end-stage renal disease. Recent studies have shown
that HRT is under-prescribed in this population of
patients. Estrogen deficiency predisposes women to serious
health problems while estrogen replacement therapy can
prevent or postpone major health problems,

such as

Alzheimer's disease, osteoporosis, and cardiovascular
disease. There is a need for more research in the areas of
menopause,

estrogen deficiency, and hormone replacement in

women with end-stage renal disease

(ESRD).

Chapter II will provide a review of literature.
Chapter III will describe methodology used for this study.

Chapter II
Review of the Literature
Studies specifically addressing hormone replacement
therapy

(HRT) in women with end-stage renal disease

(ESRD)

have been limited. Studies available for substantiating
the need for this research,
subject,

relaying expertise on the

and providing conclusions for guiding the

direction of this research are presented in this chapter.
Established researchers reviewed were focused on concerns
with potential cardiovascular and bone sparing effects of
HRT as well as gynecological issues of women with ESRD.
Hyperprolactinaemia is common among women with ESRD
and is associated with decreased osestadiol levels,
decrease in sexual function,

and depression.

Matuszkiewica-Rowinska et al.
Warsaw,

(1999) conducted a study in

Poland, to document the benefits of HRT in

premenopausal women on hemodialysis with oestrogen
deficiency. The aim of the study was to evaluate the
effect of HRT on sexual function,

serum 17B-oestradiol and

prolactin levels, and bone mineral density.
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The researchers enrolled 23 women for this 12-month
study; subjects were divided into two groups. Group I
consisted of 13 women and was the treatment group. They
received biweekly transdermal oestradine with cyclic
addition of norestisterone acetate

(Estracomb TTS 50/0.25;

Norvartis). Group II was the control group and consisted
of 10 women who received no treatment. Entry criteria
included the following: secondary amenorrhea,

serum 17B-

oestradiol concentration < 30 pg/ml, and on hemodialysis
at least 6 months. A serum PTH > 400 pg/ml, treatment in
prior 3 months with Vitamin D analogues, and
immobilization or corticosteroid therapy for the previous
12 months were exclusion criteria.

In addition, diffuse

fibrocystic disease of the breast, endometrial
hypertrophy,

and treatment with sex hormones for the

previous 5 years excluded subjects. The etiology of renal
failure for all subjects were glomeruli and interstitial
nephritis, polycystic kidney disease, diabetic
nephropathy,

and other renal causes. These were

distributed equally in both groups.
All subjects received baseline mammography and
endometrium biopsy.

In addition,

seruml7B-oestradiol

(normal range for follicular phase = 25-75 pg/ml), and
prolactin

(normal range = 66-4 90 mlU/ml)

levels were drawn

at baseline and 1, 3, 6, and 12 months in Group I, and

23

before and after the study in Group II. Pre-dialysis serum
calcium,

alkaline phosphate,

and routine biochemistries

were assayed every 3 months, and serum triglycerides,
and HDL every 6 months.

LDL,

Intact PTH levels and bone mineral

density of the lumbar spine

(L2-L4), femoral neck, and one

third distal radius were measured in all subjects before
and after the study.

In addition,

every 3 months all

subjects received a general physical and gynecological
examination as well as an interview. They were asked to
rate themselves on questions concerning libido,
activity, physical fitness, appetite, mood,
and general well-being.

sexual

self respect,

Statistics were calculated

utilizing student t tests for paired samples, with p < .05
taken as significant,

and values were expressed as mean +

SD.
Matuszkiewicz-Rowinska et al.

(1999) found after 1

month of treatment an increase in 17B-oestradiol from
20.47 + 11.69 pg/ml to 46.8 + 13.6 pg/ml
Group I. Also,

(p < .001) for

of significance was a progressive reduction

of serum prolactin concentration from 1457 + 1045 to 691 +
116 mlU/ml after 12 months of treatment with oestrogenprogestin therapy. Thus, the prolactin/oestradiol ratio
decreased from 71.0 to 13.7

(p < .001). There was no

change in PTH, alkaline phosphate,
routine biochemistries,

calcium, hematocrit,

or blood pressure readings. The
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only change in lipid profile was a moderate increase in
mean serum HDL-cholesterol
group.

(p < .01) in the treatment

In both groups, the baseline bone mineral density z

scores were depressed, with the lowest areas found at the
lumbar spine.

In Group I, an increase in bone mineral

density at all three sites was noted with significant
increases at L2-L4

(p < .05). The other two site increases

were not significant. Control Group II experienced a mild,
insignificant decrease in bone mineral density. The bone
mineral density comparison of both groups after 12 months
revealed marked differences in all three sites : distal
radius

(p < .01), femoral neck

(p < .02), and L2-L4

(p <

.05). The researchers concluded that normalization of
serum oestradiol levels in women with previous oestradiol
deficiency is sufficient to prevent bone loss and increase
bone formation.
In addition, Matuszkiewicz-Rowinska et al.

(1999)

discovered a substantial improvement in sexual function in
Group I compared to Group II. All of the women in Group I
experienced regular menses, two women in the control group
experienced a resumption in menstruation, but had
irregular cycles. Also in the treatment group,

11 out of

13 women reported a marked increase in libido, and 6 out
of 8 women who were in stable relationships either resumed
sexual intercourse or had a substantial increase in their
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sexual activity. These women also reported an increase in
physical well-being, activity, mood, mental alertness,

and

self-respect.
The researchers concluded that normalization of
oestradiol levels in premenopausal women on hemodialysis
caused a fivefold reduction in prolactin/oestradiol ratio.
These changes were accompanied by an improvement in
general well-being,

restoration of regular menses,

marked improvement in sexual function. Also,

and a

of

significance was an increase in bone mass with inhibition
of bone demineralization. The researchers suggested that
oestrogen deficiency has an important role in ureamic bone
disease in premenopausal,

amenorrheic women on dialysis.

The long survival rate of ESRD patients has caused an
increased prevalence of complications that can strongly
influence their quality of life. Hyperprolactinaemia is
frequent in these patients and associated with a decreased
oestradiol level and a decrease in sexual function.
Depression also is frequent in this population of
patients.

Decreased oestradiol levels and sexual

dysfunction may contribute to this depression as well as
decrease the perceived quality of care. This current
researcher finds Matuszkiewicz-Rowinska et al.'s study
applicable to the current research because their results
demonstrate that HRT increases general well-being.
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physical activity,

libido, and sexual function. These

factors have a significant role in the quality of life of
these patients.
Of particular interest to the current researcher was
the high mortality rate related to cardiovascular disease
in women with ESRD. Therefore,

studies exploring this

topic were reviewed.
Ginsburg et al.

(1998) conducted a study at Brigham

and Women's Hospital in Boston. The researchers
hypothesized that estrogen replacement therapy will
improve lipoproteins in postmenopausal women with ESRD.
The purpose of the study was to examine the effects of
estrogen therapy on lipoproteins.
Included in the study were women > 4 5

years old who

had been on hemodialysis > 6 months. Additional criteria
included hematocrit > 22%, normal hepatic transaminase,
and a follicle stimulating hormone > 40 lU/ml. History of
previous CVA, breast cancer, and current diabetes mellitus
requiring insulin were exclusion criteria. Of the 11
subjects who completed the study, the mean age was 61.4 +
2.7 years,
were White.

8 were African American,

1 was Hispanic,

and 2

Two subjects had noninsulin-dependent diabetes

mellitus. No subject received any estrogen replacement
therapy for 6 weeks prior to the study.
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Because of concerns of excess sex hormone levels, a
desire to minimize patient risk and the need to assess
lower dose estrogen replacement therapy,

seven subjects

entered a pilot study to evaluate estradiol levels
attained on 1 mg oral estradiol daily for 4 weeks. Based
on the results of this pilot study,

13 subjects entered a

double-blind crossover study using oral micronized
estradiol 2 mg and a placebo. The subjects were randomized
to receive either the placebo or estrogen daily for 8
weeks. After a 4-week washout period,

subjects received

the other therapy for 8 weeks. After completing the 8
weeks of placebo estrogen,

all subjects took

medroxyprogesterone acetate 10 mg daily for 1 week.
Fasting blood samples were drawn at the initiation of
the hemodialysis treatment at three different times in the
study. The first was baseline or pre-intervention,
days during the fourth week of intervention,

then, 2

and lastly,

3

days during the last week of intervention. The results
from each week were averaged and analyzed at the Lipid
Research Lab of the Nutrition Department at Harvard School
of Public Health. The following blood tests were done:
total cholesterol, HDL, HDL2, HDL3, LDL, triglycerides,
estradiol, VLDL

(including apolipoprotein Al) estradiol,

estrone, albumin, and sex hormone binging globulin

(SHBG).
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The pilot study group who took estradiol 1 mg daily
for 4 weeks was compared to the group taking 2 mg per day.
Comparisons were considered statistically significant at p
< .05. The estradiol levels in the 1-mg group increased
from 21 + 6 to 91 + 19
placebo group,
estradiol,

(p = .024). In comparison to the

statistically significant increases in

estrone, and SHBG were achieved. Total HDL

increased in all groups
and placebo),

(1 mg estradiol,

2 mg estradiol,

the mean values were 16.1%. Total HDL

concentration increased from 52.2 + 19.4 mg/dl after
placebo treatment to 60.6 + 19.6 mg/dl

(p = .046). HDL3

increased by only 9.2% and was not statistically
significant.

LDL cholesterol was unchanged for all groups.

Apolipoprotein Al increased by 24%

(p = .0002), and total

tryglycerides increased by 15.8% with daily estradiol.
However,

compared to the placebo group, neither was

statistically significant.
Ginsberg et al.

(1998) found that oral estradiol

increases total HDL by an average of 8.4 mg/dl

(16.1) and

apolipoprotein Al by 24.6% compared with the placebo
group.

Previous studies in patients with no renal failure

have suggested that comparable increases in HDL are
expected to decrease the risk of cardiovascular disease by
50%. The 1-mg dose of estradiol for 4 weeks increased HDL
by 20%, which also is a level of response that would be
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expected to decrease cardiac morbidity and mortality.

The

researchers advocated the use of 1-mg estradiol dose for
future trials to minimize the risks associated with higher
hormone levels.
Many treatments for hyperlipidemia in the ESRD
population have been evaluated,
probucol,

lovastatin,

including gemfibrozil,

and simvastatin. Many of these

lipid-lowering agents have major side effects,

such as

rhabdomyolysis and elevated hepatic transaminases.

The

researchers concluded that similar benefit from estrogen
replacement therapy may be achieved with fewer side
effects.
Ginsburg et al.

(1998) did not address the question

of whether improvements in lipoprotein parameters could
lead to comparable reductions in cardiac mortality. Larger
clinical trials are needed to determine if estrogen
replacement therapy should be routinely prescribed for
postmenopausal women with ESRD. The current researcher
finds this study applicable to her effort because the
benefits of estrogen replacement therapy have been clearly
demonstrated to reduce the risk of cardiovascular
mortality in postmenopausal women with normal renal
function. Because of the high mortality rate associated
with postmenopausal women with ESRD, estrogen therapy
should be considered for these patients. However, this
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possible benefit must be weighed against side effects of
estrogen replacement therapy,
thromboembolism,

such as venous

cholelithiasis,

and increased risk of

breast cancer.
The current researcher sought studies which
identified reproductive and or genealogical issues in
patients with ESRD.

In a study which focused on

gynecological disorders in women with renal failure,
Cochrane and Regan

(1997) undertook a prospective study

which aimed to establish the nature and extent of
gynecological disorders among 100 women with CRF (chronic
renal failure)

and or who had received a renal transplant.

Subjects were referred to the gynecology clinic by
the nephrologists. They completed a detailed questionnaire
concerning their renal disease, treatment,

and

gynecological history. They also underwent a pelvic exam
and ultrasound,

cervical smear, and serum FSH, LH,

oestradiol, and prolactin levels. Women 50 and older had a
mammogram. Of the sample
renal transplant
drug therapy

(mean age 39.6 years),

and the other 9 were on peritoneal

(mean age 42.4). Nearly 40% of the women were

referred for menstrual disorders,
symptoms,

30 were managed by

(mean age 35.9), 17 were on hemodialysis

(mean age 43.6),
dialysis

(N = 100), 44 had a functioning

13% for subfertility,

12% for menopausal

11% for contraceptive
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counseling,

and 2% for abnormal cervical smears. Only 23%

of these subjects were referred for screening and
surveillance.
The researchers found that of the 62 women who were
menstruating,

81% had menorrhagia and 35% were

amenorrheic. Of the 33 women with amenorrhea,

30 were

menopausal. Only 12% of the 100 women had a normal
menstrual cycle. Twelve women were referred with a
diagnosis of menopause, but after examination of all
subjects, the researchers discovered 23 women who were
menopausal. Of these women

(n = 35), 20% were less than 40

years old, and only two were on HRT. A total of 4 9 women
were enrolled in the study who were less than 40 years of
age; of these,

14% had primary ovarian failure.

Cochrane and Regan
required contraception;

(1997)

found 53 of the 100 women

13 of these had never had

contraceptive counseling. An intrauterine device was found
in 5 patients, which is not recommended for these patients
as it may exacerbate menorrhagia and increase the risk of
infection in immunosuppressed women. There also were 24
women identified who could potentially become pregnant; of
these,

92% had involuntary infertility.

Only 2 women were originally referred for an abnormal
cervical smear. After initial examination of all subjects,
8 more were identified to have an abnormal cervical smear.
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Of these women,

4 were diagnosed by colposcopy with

cervical intraepithélial neoplasia

(CIN), and 1 was found

to have invasive cervical carcinoma and underwent
hysterectomy.
Prolactin levels in all subjects were normal except
for those on hemodialysis, which were elevated. The
researchers concluded that 85% of these patients had
menstrual disorders, mainly menorrhagia, which was of
concern because heavy vaginal bleeding worsens the anemia
of CRF and may necessitate blood transfusion. Transfusions
are undesirable as they cause atypical and cytotoxic
antibodies which decreases the chance of successful organ
matching. Also, treatment with erythropoetin is expensive
and may be withheld in women with persistent menorrhagia.
For treatment of menorrhagia, the researchers supported
the use of high-dose medroxyprogesterone acetate
(Provera).
Cochrane and Regan

(1997) concluded that menstrual

disorders were not reduced after renal transplantation,
and approximately 33 subjects were amenorrheic. This
menstrual disorder was not perceived to be a problem by
the nephrologists. Of the 35 women identified as
menopausal,

all were recommended and encouraged to

initiate HRT. The researchers cited these patients to be
at high risk for osteoporosis because of the cumulative
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effects of ovarial failure, long-term steroid therapy,

and

CRF. Cochrane and Regan also found that contraceptive
counseling had been inappropriate or nonexistent,

and they

recommended all women with CRF seek contraceptive
counseling. Low-dose combined oral contraceptives were
recommended for most patients and had the added benefit of
improved cyclic control. Severe hypertension and active
systemic lupus were cited as contraindications to oral
contraceptive. The researchers also identified an
eightfold increase in cervical dyskariosis and related
this to the use of immunosuppressive drugs. Of
significance is the fact that 80% of these abnormalities
would have been missed had the researchers not preformed
cervical smears on all patients. Therefore,

these

researchers recommended that women with CRF on
immunosuppressive therapy undergo annual cervical
screening.
Cochrane and Regan

(1997) confirmed the value of

regular gynecological surveillance for seemingly
asymptomatic women with chronic renal failure based on the
unrecognized pathology identified in the study. This
current researcher finds this study applicable to her
study because of the high incidence of undetected
gynecological disorders in this population of patients.
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These disorders could potentially complicate and aggravate
the management of renal disease.
Of interest to the researcher were patient profiles
of current HRT use. Therefore,

studies that included

demographic and clinical data of patients who were
prescribed HRT were reviewed.
In 1999, Gillen,

Gipson,

and Stehman-Breen conducted

a secondary analysis of data from the United States Renal
Data Systems
Study

(USRDS)

Dialysis Morbidity and Mortality

(DMMS) Wave 2. They sought to assess the prevalence

and predictors of HRT in postmenopausal women with ESRD.
The DMMS had detailed demographic, behavioral,

and

medical history of patients with ESRD. This prospective
study included a random sample of patients from 25% of the
dialysis facilities in the United States that opened after
January 1, 1994. The subjects were at least 18 years of
age, had been on dialysis for more than 90 days, and
qualified for Medicare.

Subjects who were previously

transplanted and or were on home dialysis were excluded
from the study.
personnel.

Data were collected by dialysis facility

Patient demographic and behavior data obtained

were gender, age, race, weight,
employment,
medications,

height, marital,

and educational status. Clinical data included
co-morbid conditions,

and exercise frequency.
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Of the DMMS sample, Gillen et al. selected 1,499
subjects for the secondary analysis. All females age 45
and older were considered postmenopausal and included in
the study.

From the medication list, the use of estrogen,

progesterone,

or a combination was determined for each

subject. The use of HRT among the subjects was predicted,
utilizing logistic regression to estimate the independent
contribution of demographic, behavioral,

and medical

history variables. The odds ratios were interpretable as
the adjusted odds of being prescribed HRT for each
variable of interest. Confidence intervals were
established using the estimated standard error of the
coefficient

(Bl) from the logistic regression analysis.

The relationship between HRT and triglycerides and
cholesterol were estimated using linear regression and
reported as the mean difference in triglyceride or
cholesterol between subjects who used HRT and those who
did not, along with 95% confidence intervals.

SPSS

statistical software was used to analyze the data.
Gillen et al.

(1999) determined the prevalence of HRT

prescription among the subjects was 10.8%
1,499).

(162 out of

Prescription prevalence was highest in the fifth

decade of life

(18%) and lowest in the eighth decade

Women in their 4 0s

(7%).

received HRT 15% of the time, while

those in their 60s and 70s had a prevalence of 8%.
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Ninety-five percent of the subjects were prescribed
estrogen and or progesterone separately, whereas the
remaining subjects
preparation.

(n = 8) were prescribed a combination

For each decade of life,

subjects were 2 6%

less likely to be prescribed HRT. This was compared to a
previous study which cited HRT use in the general
population which was 34%.
The researchers determined predictors of HRT use
among the subjects,

including age, ethnicity,

education,

and ambulation status. All predictions were made after
adjusting for education,

race, and independent ambulation.

Black subjects were 50% less likely to be prescribed, HRT
than white subjects

(aOR=0.50, p < .002). Subjects with a

college degree were threefold more likely to be prescribed
HRT than those with a high school degree or less
(aOR=2.98, p < .001). Ambulatory women were nearly twofold
more likely to be prescribed HRT than those who were not
ambulatory

(aOR=l.99, p = .05). In addition,

subjects with

diabetes were less likely to be prescribed HRT than
nondiabetics
11.0 mg/dl

(OR=0.65, p < .01). Cholesterol levels were

(95% Cl, 1.5 to 20.5) higher in subjects

prescribed HRT compared to women not on HRT. Triglyceride
levels were 47.2 mg/dl

(95% Cl, 18.9 to 75.5) points

higher in women using HRT.
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Gillen et al.

(1999) cited factors which might

explain the overall low rate of HRT prescription in
postmenopausal women with ESRD, including physician
attitude,

ethnicity,

secular trends, and geographic

location. Also, variation in demographic distribution
between women with and without ESRD could account for much
of the difference in the rate of HRT prescription.
The researchers concluded that HRT use in the general
population is greater than in women with ESRD. The most
important predictors of HRT prescription in postmenopausal
women with ESRD were younger age, higher education. White
race, and ambulatory status. The current researcher finds
this study applicable to her study and agrees with the
researchers that targeting groups of women who are likely
to benefit from, but least likely to be prescribed,

HRT

could increase the prescriptions of HRT in this
population.
A study of women with ESRD to identify menstrual
patterns,

contraception,

HRT use, and sexuality issues was

conducted by Holley, Schmidt, Bender, Dulmer,

and Schiff

(1997). The sample was 191 women receiving hemodialysis at
four dialysis facilities in the United States.

Inclusion

criterion was women less than 55 years old when they began
dialysis. Medications were reviewed for estrogen
replacement only. Women less than 55 years of age
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completed the questionnaire

(N = 76), and their responses

formed the data for the study. Women older than 55 were
excluded from the study

(n = 115) and only completed part

of the questionnaire. The demographic data on the
questionnaire included age, race, mode of dialysis,

age at

start of and time on dialysis, and use of recombinant
erythropoietin. Also included on the survey were questions
concerning pregnancies, menstrual cycle,

sexual activity,

use of birth control pills and HRT, and questions
concerning preventative health care. Of these subjects,
were on hemodialysis,
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and 24 were on peritoneal dialysis.

Statistical analysis utilized the chi-square test for
comparison of proportions.

In addition,

the Mann-Whitney Ü

test and student t test were used when appropriate.

Data

were represented as mean values + standard deviation or
medians,

and £ < .05 was considered significant.

Of the 7 6 subjects in the study group,

70%

(n = 53)

had been pregnant at least once; 4 (2%) of the pregnancies
occurred after dialysis was initiated. Of the 4 subjects
who became pregnant while on dialysis,

only 2 reported

birth control discussions by their nephrologists or
primary health care provider, and 1 continued to be
sexually active without using birth control. The response
of subjects on hemodialysis
dialysis

(n = 52) and peritoneal

(n = 24) were summed and analyzed together as
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there was no significant difference in the responses
between groups. Holley et al. found that 32 of the
subjects were currently menstruating; of those,

59%

(n =

19) reported irregular menses. The sample reported heavy
flow with clots when compared with flow before starting
dialysis

(14 of 22

the study subjects,
these,

[64%] vs. 18 of 48 [38%]: £ = .05). Of
19

(n = 28) were postmenopausal; of

5 reported menopause occurring after starting

dialysis. Although the median age of the subjects was 43,
only 50% reported being sexually active; postmenopausal
women were less likely to be sexually active

(4 of 17 vs.

30 of 49; £ = .01). Of these sexually active women,
= 27) reported using birth control. Only 13%

36%

(n

(n = 9)

reported discussing birth control options with their
nephrologists. Of the sample,
papanicolaous smear, and 73%
Of the study subjects,
53%

63%

(n = 47) had yearly

(n = 50) had a mammogram.
19 (28%) were postmenopausal;

(n = 10) reported experiencing menopause naturally.

Only one of the postmenopausal women received estrogen
replacement therapy, the remainder either did not answer
the question or were not using any form of HRT. Of the 20
subjects who did not answer the question concerning HRT
(24 of 44), Holley et al. determined through a review of
the medication list that 5% were on estrogen replacement
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therapy. Of 113 subjects 55 and older,

only 5% were

receiving estrogen replacement therapy.
Holley et al.

(1997) concluded that 42%

(n = 32) of

the subjects were currently menstruating, which contrasts
with earlier researchers who determined 10% of
premenopausal women on dialysis had regular menses. Holley
et al. established that the use of recombinant
erythropoietin contributes to the significant increase in
menses in these subjects. Ureamic women have an acyclic
pattern of gonadotropin release because of impaired
estradiol stimulation, which possibly is related to
hyperprolactimemia. In addition, high prolactin levels
were postulated to be contributory to decreased libido and
lower frequency of sexual intercourse among females with
ESRD. The researchers also concluded that some features of
contemporary dialysis care, such as the use of recombinant
erythropoietin with improved hematocrits and adequacy of
dialysis, may be related to reduced prolactin levels.
The current researcher finds the overall low rate of
hormone prescription in Holley et al.'s sample of
postmenopausal women is a concept of this current study.
Also, of particular interest was the low incidence of
counseling to premenopausal women by their nephrologists
or primary health care provider. Holley et al. recommended
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further study to validate their findings and determine why
the rates of HRT were so low.
Lyhne and Pedersen

(1995) conducted a 2-year

prospective study of 23 dialysis patients at Odense
University Hospital in Denmark. The purpose of the study
was to evaluate the medical treatment of renal
osteodystrophy,

a condition found frequently in patients

with ESRD. The subjects included 12 women and 11 men.
Median age for females was 54
men

(range 27 to 68) and 60 for

(range 24 to 68). Inclusion criteria were initiation

of dialysis between 1985 and 1990, peritoneal dialysis as
first mode of dialysis, and less than a 2-month
interruption in treatment. Exclusion criteria were
previous use of steroids, oestrogen in any form, or
hormonal contraceptives. The cause of renal failure was
equally distributed between male and female subjects and
primarily included glomerulonephritis, diabetic
nephropathy,

and polycystic kidney disease.

At baseline and every 6 months during the study, bone
mineral content was measured by single photon
absorptiometry at the fixed radius of the dominant
forearm. The mean value was calculated by the average of
four 2-dimensional scans. This method has an accuracy of
0.958

(the coefficient of correlation between bone mineral

content and bone calcium content) and 0.8 - 1.4%
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reproducibility.

In addition,

serum 1,25

(OH) 2 D3 levels

were measured at the beginning of the study and every 6
months. Baseline and monthly serum total calcium,
phosphate,

total alkaline phosphate,

levels were also measured

albumin,

and bicarbonate

(Lyhne & Pedersen,

1995).

Daily treatment modality included four dialysis
exchanges per day, using Ca++ 3.5 mEq/L dialysate bags,
oral phosphate binder, and oral Vitamin D3

(l-alpha-0H-D3)

supplementation. The median dose of Vitamin D3 over the
24-month study period was 0.25 for both males and females.
The mg/kg median dose of phosphate binder for both genders
during the study was 12. Serum 1,25

(OH) 2D3 levels and

bone mineral content were not taken into account when
prescribing doses.
Lyhne and Pedersen

(1995) utilized Wilcoxon's test of

paired data and Mann-Whitney's test of unpaired data to
evaluate results. Ranges or medians were used to describe
results, with calculations of the p and 95% confidence
limits of the median. Kendall's rank test was used for
correlation tests. The bone mineral content was expressed
in percentage of the initial value.
The researchers determined that the bone mineral
content significantly decreased

(p < .001)

for female

subjects over the 24-month study period when compared to
male subjects. The median decrease of bone mineral content
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for females was 12% over 2 years, but was nonsignificant
for males subjects

(p < .01). No significant correlation

emerged between age and bone mineral content change in
either group

(Kendall's T = 0.182 and 0.067,

respectively). (Comparative findings in the general
population has shown bone mineral content decreases of 1%
per year in females ages 35 to 65 years and a 2% decrease
during perimenopause.) The researchers found no
significant difference in oral vitamin D3 dose or serum D3
levels in either group.

Female subjects demonstrated a

significant increase in serum Ca++
decrease in serum phosphate

(p < .05), as well as a

(p < .05), while male subjects

showed no significant change in either. However, there was
a significant decrease in serum albumin and body weight in
the male group

(p < .01 and p < .05, respectively), but

only slight decreases in the serum albumin and maintenance
of body weights
months)

(100% of weight at start vs. 105% at 24

in the female group.

Lyhne and Pedersen

(1995) concluded that the women

who had peritoneal dialysis as first mode demonstrated a
significant decrease in bone mineral content as compared
to men, even though lab values and maintenance of body
weight demonstrated better treatment outcomes in the
female groups. The researchers also concluded that this
significant decrease compared to the general population
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suggest severe skeletal imbalances in the female subject
group which could indicate a sex hormone-related
disturbance.
Summary
There were no empirical studies in the review of
literature that specifically identified barriers and
facilitators to HRT initiation; however, there were
numerous studies that cited the benefits to correction of
estrogen deficiency among postmenopausal women with renal
failure.
Several previous studies have examined reproductive
and sexuality issues among women with renal failure.
Matuszkiewicz-Rowinska et al.

(1999) conducted a study of

23 postmenopausal women with renal failure to evaluate the
effect of HRT on sexual function, estrogen and prolactin
levels, and bone mineral density. The researchers
concluded that normalization of estradiol levels in these
women with previous oestradiol deficiency is sufficient to
prevent bone loss, increase bone formation, and improve
libido. Cochrane and Regan

(1997) undertook a prospective

study which aimed to establish the nature and extent of
gynecological disorders among 100 women with ESRD and or
who had received a renal transplant. The researchers found
that reproductive problems were frequent and unrecognized
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and menopausal symptoms were undertreated. Of the
subjects,

58% had a menstrual disorder, with uncontrolled

menorrhagia being a significant problem and 45% were found
to be postmenopausal. The researchers determined that 80%
of the abnormalities identified would have been missed had
they not performed cervical smears on all patients.

In

another study of women receiving dialysis, Holley et al.
(1997)

identified sexuality issues, menstrual patterns,

contraception,

and HRT use. The researchers reported the

median age for menopause was 47 years, and only one
postmenopausal woman received HRT.
The study conducted by Lyhne and Pedersen

(1995) to

evaluate the treatment of renal osteodystrophy found a
significant decrease in bone mineral content in women as
compared to men. The researchers concluded that women who
had peritoneal dialysis as first mode demonstrated a
significant decrease in bone mineral content as compared
to men even though lab values and body weight demonstrated
better treatment outcomes in the female groups. Lyhne and
Pedersen also concluded that the significant decrease in
bone mineral content of females on dialysis suggest severe
skeletal imbalances which could indicate a sex hormone
related disturbance.
Few studies have specifically addressed current HRT
prescription.

In 1999, Gillen et al. conducted a secondary
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analysis of 1,499 females ages 45 and older and on
dialysis using data from the United States Renal Data
Systems

(USRDS)

Dialysis Morbidity and Mortality Study

(DMMS) Wave 2. They sought to assess the prevalence and
predictors of HRT in postmenopausal women with ESRD.
Gillen et al.

(1999) determined the prevalence of HRT

prescription among the subjects was 10.8%

(162 out of

1,499); and for each decade of life, subjects were 26%
less likely to be prescribed HRT. Gillen et al.

(1999)

cited factors which might explain the overall low rate of
HRT prescription in postmenopausal women with ESRD,
including physician attitude, ethnicity,

secular trends,

and geographic location. The most important predictors of
HRT prescription in postmenopausal women with ESRD found
by their researchers were younger age, higher education,
white race, and ambulatory status.
Recent studies have documented a significant decrease
in CVD mortality among women who received HRT. Ginsburg et
al.

(1998)

conducted a study of women ages 45 years and

older with renal failure to examine the effects of
estrogen therapy on lipoproteins. The researchers found a
20% increase in HDL after only 4 weeks of oral estradiol 1
mg. Previous studies in patients with no renal failure
have suggested that comparable increases in HDL are
expected to decrease the risk of CVD by 50%. Many
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treatments for hyperlipidemia in the ESRD population have
been evaluated,
lovastatin,

including gemfibrozil, probucol,

and simvastatin. Many of these lipid-lowering

agents have major side effects,

such as rhabdomyolysis and

elevated hepatic transaminases.

The researchers concluded

that similar benefit from estrogen replacement therapy may
be achieved with fewer side effects, and they advocated
the use of 1 mg estradiol for future trials to minimize
the risks associated with higher hormone levels.
In conclusion, the review of literature supported the
current study which found that approximately 10% of
postmenopausal women receive HRT. The literature review
also supported the need for more research concerning
menopause among women with ESRD.

Chapter III
The Method
This researcher sought to identify the barriers and
facilitators to nephrology health care providers
initiating hormone replacement therapy

(HRT) in

postmenopausal women with end-stage renal disease

(ESRD).

Nephrology health care providers in Alabama, Mississippi,
and Tennessee were surveyed utilizing a researcherdeveloped tool, Tramel's Questionnaire, to identify
current HRT prescribing practices. An open-ended question
was provided for additional information.
chapter are study design,

Included in this

setting, population and sample,

instrumentation, procedures,

and data analysis.

Design of the Study
A descriptive study design was used since the
researcher sought to explore and document aspects of a
setting as it occurs naturally (Polit & Hungler,

1999).

The aim of this descriptive study was to identify the
barriers and motivators to nephrology health care
providers initiating HRT in their postmenopausal clients.
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Setting,

Population,

and Sample

The setting for this study was outpatient
hemodialysis facilities in Alabama, Mississippi,

and

Tennessee. The total number of dialysis facilities in
these three states is approximately 300. The patient
census for each unit varies from 10 to 100 patients.
Currently,

there are approximately 15,000 ESRD patients

receiving dialysis at these facilities. The target
population was nephrology health care providers in
Alabama, Mississippi,

and Tennessee who care for

postmenopausal women aged 45 years or older who have had
ESRD for more than 6 months. There are an estimated 200
nephrologists in the tri-state region

(T. Wooldridge, MD,

personal communication. May 8, 2001). The target sample
consisted of 100 subjects who met criteria and completed
and returned the questionnaire. The actual sampling was 26
which represents a 17% return.
Instrumentation
Tramel's Questionnaire,

a researcher-developed

instrument, was utilized to collect data concerning
demographic and descriptive practices of nephrology health
care providers in Alabama, Mississippi,

and Tennessee

regarding HRT in their postmenopausal women with ESRD. The
instrument is assumed to face validity within the confines
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of this study as it was reviewed by a panel of research
experts and piloted for clarity by a health care provider
in nephrology.

Since there is no summative score,

questions were analyzed independent of each other.
Procedures
Prior to implementation of this study, permission was
obtained from the Mississippi University for Women
Committee on Use of Human Subjects in Experimentation

(see

Appendix A ) . ESRD facilities addresses were obtained from
Network 8, a Health Care Financing Committee

(HCFA), data

collection agency. Ten dialysis facilities in Alabama,
Mississippi,

and Tennessee were each sent a packet of five

of the following : Trame 1's Questionnaire

(see Appendix B ) ,

cover letter with information about the study
Appendix C ) , and a stamped,

(see

self-addressed return

envelope. A follow-up postcard was mailed to the dialysis
facilities 2 weeks later

(see Appendix D ) . This approach

only stimulated five returns. A telephone conference of
research committee members was set up to choose an
alternative data collection method. The committee decided
that personal contact per telephone with nephrology health
care providers was appropriate. Thirty nephrologists were
contacted in Alabama, Mississippi,

and Tennessee; packets

were faxed to the care provider with the same information
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that was originally sent

(see Appendix E ) . Employing both

methods of data collection, a final sample of 26 (17%
return) was achieved. Confidentiality was maintained as no
survey had any identifying data. Return of the
questionnaire indicated the subject's consent to
participate.

Data collection took place during the months

of April and May 2001.
Data Analysis
Questions 1 and 2 are demographic questions and
require a check

(^) only response. Questions 3, 4, 5, and

6 deal with patient load and require either a check
fill-in-the-blank response.

(/) or

Descriptive statistics

including frequency distribution, percentages,

and means

were utilized to analyze these questions. Questions 7, 8,
and 9 concern barriers and facilitators to HRT initiation
and required the health care provider to rank five
responses in order of importance:

1 (the most prevalent)

and 5 (the least prevalent). Question 10 was an open-ended
question and prompted the nephrology health care provider
to write comments relevant to the research study. Only
four responses were received for Question 10. Content
analysis was used to identify themes; facilitators and
barriers to HRT initiation were discussed in the openended question. Among the comments were the need for more
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research,

lack of educational opportunities,

and inability

to monitor the patient if prescribed HRT.
Summary
The purpose of this study was to describe
facilitators and barriers to initiation of HRT by
nephrology health care providers among postmenopausal
women with ESRD. A researcher-developed questionnaire.
Trame1's Questionnaire, was used to collect data.
Descriptive statistics,

including ranking,

distribution and percentages,

frequency

were utilized to analyze the

data.
Chapter III described empiricalization of the study.
Chapter IV will discuss the findings, and Chapter V will
describe the outcomes of the study.

Chapter IV
The Findings
The purpose of this descriptive, nonexperimental
study was to identify the factors that influence
nephrology health care providers to prescribe hormone
replacement therapy

(HRT) for postmenopausal women under

their care. The research questions that guided this study
were as follows :
1. What are the facilitators cited by nephrology
health care providers to initiate HRT for postmenopausal
women with end-stage renal disease?
2. What are the barriers cited by nephrology health
care providers to initiate HRT for postmenopausal women
with end-stage renal disease?
Within Chapter IV, a detailed description of the
sample, results of data analysis,

and additional findings

are presented.
Description of the Sample
One hundred fifty researcher-developed questionnaires
were mailed to nephrology health care providers in
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Alabama, Mississippi,
questionnaires

and Tennessee. Twenty-six

(17%) were returned. The convenience sample

consisted of nephrology health care providers who cared
for women, ages 47 years and older, who had renal failure
for more than 6 months. Twenty-three

(88.4 6%) of the

subjects were board-certified in nephrology,

1 (3.85%) was

a medical doctor, and 2 (7.69%) were nurse practitioners.
The sample represented three states: Alabama 2 6.92
7), Mississippi,

52.31%

(n =

(n = 11), and Tennessee 26.92%

(n

= 7). The average number of years practicing as a health
care provider was 12.8 years,

and the majority

(88.77%)

of

the sample were male. Questions regarding patient
population also were included. The majority

(26.92%)

currently provided care for 301 to 400 ESRD patients ; the
current range for patients seen was 101 to 700. Subjects
reported caring for an average of 138 female patients who
met inclusion criteria. Eleven

(42.31%) of the male health

care providers identified that 6% to 10% of their eligible
postmenopausal women were receiving HRT, while the 2
female health care providers identified that > 50%

(7.6%)

of their eligible women patients were on HRT. Nephrology
health care providers were asked how many continuing
education units

(CEUs) they have received regarding HRT or

menopause. An overwhelming 7 6.92%

(n = 20) reported having

received no CEUs during the past year; 23.08%

(n = 6)

55

reported 1 to 5 CEUs. Only 12 (46.15%) reported CEUs in
the last 5 years and 10

(38.46%)

still reported no CEUs.

Results of Data Analysis
The researcher sought to identify facilitators and
barriers to initiation of HRT among postmenopausal women
with renal failure. The first research question was as
follows: What are the facilitators cited by nephrology
health care providers to initiation of HRT among
postmenopausal women with ESRD?

Questions 7 and 9 on

Tramel's Questionnaire concerned facilitators.
Question 7 the care provider ranked,
importance,

For

in order of

reasons they would initiate HRT among their

postmenopausal patients. The majority ranked surgicallyinduced menopause as the number one reason to initiate
HRT,

and all respondents ranked cardiovascular disease

(CVD) protection as the least likely reason to initiate
HRT. These factors are regarded as health facilitators
(see Table 1).
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Table 1
Health Facilitators to HRT Initiation by Nephrology Health
Care Providers Using Rank Order by Question

Question

State®

Rank

7. Reasons you would initiate
HRT in postmenopausal women
under your care:
Surgically-induced menopause
Patients ask for it
Relief of menopausal symptoms
Prevention of osteoporosis
Cardiovascular disease protection

AL
AL
AL
AL
AL

1
2
3
4
5

Surgically-induced menopause
Patients ask for it
Relief of menopausal symptoms
Prevention of osteoporosis
Cardiovascular disease protection

MS
MS
MS
MS
MS

1
2
3
4
5

Surgically-induced menopause
Relief of menopausal symptoms
Patients ask for it
Prevention of osteoporosis
Cardiovascular disease protection

TN
TN
TN
TN
TN

1
2
3
4
5

Note.

AL = Alabama. MS - Mississippi,

^Alabama

(n = 7), Mississippi

TN = Tennessee.

(n = 11), Tennessee

(n = 7)

For Question 9 care providers ranked factors that
would make it easier or more convenient to prescribe HRT.
The majority ranked the need for more research prior to
their initiating HRT as number one. The development of a
pocket guide was considered last as a facilitator by all
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respondents. These factors are considered external
facilitators and are listed in Table 2.
Table 2
External Facilitators to HRT Initiation by Nephrology
Health Care Providers Using Rank Order by Question

Question

State®

Rank

9. What would make it easier or more
convenient for you to prescribe HRT?
Journal articles
More research
Presentations
Continuing education units
Pocket guide
More research
Presentations
Journal articles
Continuing education units
Pocket guide
More research
Presentations
Journal articles
Continuing education units
Pocket guide
Note.

(CEUs)

(CEUs)

(CEUs)

AL
AL
AL
AL
AL

1
2
3
4
5

MS
MS
MS
MS
MS

1
2
3
4
5

TN
TN
TN
TN
TN

1
2
3
4
5

AL = Alabama. MS = Mississippi, TN = Tennessee

^Alabama

(n = 7), Mississippi

(n = 11), Tennessee

(n == 7) .

The second research question was as follows: What are
the barriers to initiation of HRT among postmenopausal
women with ESRD? For Question 8 nephrology health care
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providers ranked,

in order of importance,

reasons they

would not initiate HRT. The majority ranked physician
liability as the number one reason they would not initiate
HRT and ranked CVD as the least important reason they
would not initiate HRT

(see Table 3).

Table 3
Barriers to HRT Initiation by Nephrology Health Care
Providers Using Rank Order by Question

Question

State®

Rank

8. Reasons you would not initiate
HRT in postmenopausal women
under your care
MD liability
Unsure of type and dose to prescribe
View as primary care/gyn
Concerns of adverse effects
Preexisting cardiovascular disease

AL
AL
AL
AL
AL

1
2
3
4
5

View as primary care/gyn
MD liability
Preexisting cardiovascular disease
Concerns of adverse effects
Unsure of type and dose to prescribe

MS
MS
MS
MS
MS

1
2
3
4
5

TN
TN
TN
TN
TN

1
2
3
4
5

8. Reasons you would not initiate
HRT in postmenopausal women
under your care
MD liability
View as primary care/gyn
Concerns of advert effects
Preexisting cardiovascular disease
Unsure of type and dose to prescribe
Note.

AL = Alabama. MS = Mississippi, TN = Tennessee.

®Alabama

(n = 7), Mississippi

(n = 11), Tennessee

(n = 7)
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Only 4 subjects responded to Question 10 on Tramel's
Questionnaire. This open-ended question allowed for
comments relevant to this study. There was no emergent
theme. However, the researcher took the liberty of
classifying responses as either facilitators or barriers.
Facilitators
I would definitely like to see more research
concerning HRT in our patient population.
[External facilitator)

Presentations, especially for nurse
practitioners in nephrology, would be helpful.
Barriers
I am based in an acute care setting and not
directly involved in prescribing routine
medications and would not have the opportunity
to monitor the patient in this setting.

I feel that nurse practitioners practicing in
nephrology do not have enough educational
opportunities specifically addressing the ESRD
patient on the local level.

Coverage and financial issues are barriers to
attending national meetings.
Limitations
The researcher identified the following potential
limitations for this study. A sample bias due to limited
geographic setting and small sample size could have been
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present which would prevent generalization of the results.
However, due to limited time and financial support, the
researcher made efforts to include at least representation
from three states. Opportunity to participate was provided
for 150 prospective nephrology health care provider.
There were some methodological constraints. The
researcher-developed instrument had no validity
established and may not have represented all facilitators
or barriers for choice. However, the researcher did
identify potential facilitators and barriers to HRT
prescription from the review of literature.

Further, the

questions were reviewed by a nephrology health care
provider and a research committee of experts. The
instrument was assured to have face validity within
confines of this study. Another methodology concern to
this researcher was the subject recruitment process. The
mailed survey process failed as it only stimulated five
respondents, personal contact by phone was then made with
45 nephrology health care providers. This second process
stimulated 21 respondents. These subjects may have
responded to please the researcher.
Summary
The purpose of this study was to describe
facilitators and barriers to initiation of HRT among
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postmenopausal women with ESRD. Analysis of responses
recorded on Tramel's Questionnaire regarding these factors
was described in this chapter. The sample consisted of 26
nephrology health care providers who currently practice
and care for ESRD patients in Alabama, Mississippi,

and

Tennessee. Only two respondents were nurse practitioners.
Descriptive statistics,

including frequency distribution,

percentage and ranking, were utilized to analyze the data.
Nephrology health care providers were 80.77%

(n = 21) male

and practiced nephrology for an average 12.8 years. The
average number of postmenopausal women under their care
was 138 while 42.31%

(n = 11) reported prescribing HRT for

these women. Tramel's Questionnaire reported an
overwhelming 76.92%

(n = 20) received no CEUs during the

past year while only one to five CEUs were reported during
the last 5 years by the majority of nephrology health care
providers

(42.31%, n = 12). Health facilitators ranked as

number one were surgically-induced menopausal.

External

facilitators that ranked as number one was the need for
more research in the area of HRT for women with renal
failure. The number one ranked barrier to HRT initiation
was concerns of physician liability.

Chapter V
The Outcomes
The population of postmenopausal women in the United
States is increasing at an exponential rate.

In 1990 there

were 28.7 million women older than 55 years of age; by the
year 2020 this group is estimated to be 45.9 million.

In

1999 over 31 million women began the menopausal transition
(Lobo,

1999). As the general population ages, the number

of postmenopausal women with end-stage renal disease
(ESRD) also will increase. The prevalence rate for ESRD
among postmenopausal women was 607 per million in 1991 and
had climbed to 931 per million in 1997
2000). Cardiovascular disease

(Mattix & Singh,

(CVD), osteoporosis, and

dementia are three disease processes that profoundly
affect the quality of life and health of ESRD patients who
are menopausal

(D. Arnold, personal communication. May 14,

2001).
Nephrology health care providers have ignored the
issue of hormone replacement therapy

(HRT) in their

postmenopausal patients despite mounting evidence that
estrogen therapy could possibly decrease morbidity and
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mortality and positively influence quality of life
& Singh,

2000).

(Mattix

In an effort to better understand the

disparity of HRT prescription in women with ESRD,

this

researcher explored the prescription practices of
nephrology health care providers regarding initiation of
HRT. The research questions that guided this study were as
follows :
1. What are the barriers cited by nephrology health
care providers to initiate HRT for postmenopausal women
with end-stage renal disease?
2. What are the facilitators cited by nephrology
health care providers to initiate HRT for postmenopausal
women with end-stage renal disease?
Pender's Health Promotion Model was the theoretical
framework used to guide this study. Within this chapter
the outcomes,

implications, and recommendations that

evolved from this study are presented.
Description of the Sample
A convenience sample of 26 nephrology health care
providers who care for women, are at least age 47 years
old, and have had renal failure for more than 6 months.
The majority

(88.46%) of the nephrology health care

providers were board certified in nephrology, were
practicing in Mississippi

(52.31%), and were male
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(88.77%) . The average number of years practicing as a
health care provider was 12.8 years. Questions regarding
patient population also were included on the
questionnaire. The majority

(26.92%)

are health care

providers for 301 to 400 ESRD patients; the range for
patients seen was 101 to 700. Nephrology health care
providers reported caring for an average of 138 female
patients age 47 and older, and the majority

(42.31%, n =

11) reported 6-10% of these women currently received HRT.
The researcher sought to determine the number of
continuing education units

(CEUs) care providers had

received regarding HRT or menopause. An overwhelming
76.92%

(n = 20) reported having received no CEUs during

the past year.
Summary of Significant Findings
The research questions that guided this study were as
follows :
1. What are the barriers cited by nephrology health
care providers to initiate HRT for postmenopausal women
with end-stage renal disease?
2. What are the facilitators cited by nephrology
health care providers to initiate HRT for postmenopausal
women with end-stage renal disease?
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Using a ranking format the number one health
facilitator cited by nephrology health care providers to
initiate HRT was surgically-induced menopause, and the
number one reported external reason nephrology health care
providers would initiate HRT was more research to validate
benefits verses adverse effects within this population of
patients.

The most ranked barrier for the nephrology

health care providers to initiate HRT was concern of
liability.
Discussion Related to Findings
Since there were no empirical studies that
specifically dealt with barriers and facilitators to
prescribing HRT, the findings of this research can neither
be supported nor refuted. Of particular interest to the
current researcher were established facilitators of HRT
such as the prevention of osteoporosis, CVD, dementia,

and

quality-of-life improvement in women eligible for HRT who
have renal failure. Clinical evidence to support the use
of HRT as primary prevention clearly exists; however,
nephrology health care providers seem to ignore this
treatment and opt not to prescribe HRT to their
postmenopausal patients. There was support found
establishing the preventative benefits of HRT by
Matuszkiewicz-Rowinska et al.

(1999) who concluded that
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normalization of serum oestradiol levels with use of HRT
is sufficient to prevent bone loss and increase bone
formation. Nephrology health care providers in this
current study ranked that response as number four in order
of importance for initiating HRT.
Consideration of HRT as a preventive action for CVD
was confirmed by Mattix and Singer

(2000). These

researchers concluded that CVD in patients with renal
failure had reached epidemic proportions and that 42% of
all deaths in women age 45 to 64 years was due to CVD.
Ginsburg et al.

(1998) also contributed to the position of

HRT as a preventive treatment when they determined that
oral estradiol increases total HDL. Previous studies in
patients with no renal failure have suggested that
comparative increases in HDL are expected to decrease the
risks of CVD by 50%. For the current study,

subject

responses did not support the concern for prevention of
CVD as they ranked that response as number five, or last
in order of importance on Question 7.
There were concerns in Ginsberg et al.'s

(1998)

study

about side effects of estrogen replacement therapy among
women with renal failure. Question 8 addressed this issue.
When the subjects ranked reasons they would not initiate
HRT, they chose concerns of adverse effects of HRT as

67

number three of five, which does not support Ginsburg et
al's position.
Matuszkiewicz-Rowinska et al.

(1999) discovered a

substantial improvement in sexual function, mood, and
mental alertness,
being,

and an improvement in general well

factors that have a significant role in quality of

life. Relief of symptoms of menopause as a response, which
would contribute to quality of life, was identified as a
selection to initiate HRT. Care providers ranked this as
number three. Also,

"patients ask for it" was the number

two response which somewhat supports MatuszkiewiczRowinska et al.

(1999) research for when patients ask for

HRT there is an implied need to feel better.
Gynecological surveillance is important to all women
with ESRD. Cochrane and Regan

(1997) confirmed the value

of gynecological surveillance in that 80% of abnormalities
found in their subjects would have been missed had the
researchers not performed cervical smears on all patients.
Cochrane and Regan also found 53 of the 100 women required
contraception and that counseling in this regard had been
inappropriate or nonexistent. The current study results
support the need for gynecological surveillance as the
average number of female patients age 47 and older seen by
the nephrology health care provider was 138 representing
42% of all their patient.
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Eleven

(42.31%) of the male health care providers

identified that 6-10% of their eligible postmenopausal
women were receiving HRT, while the two female health care
providers identified that > 50%

(7.6%) of their eligible

female patients were on HRT. This finding supports the
Health Promotion Model in that modifying factors,
gender,

such as

race, and age, directly influence health-promoting

behaviors.
Gillen et al.

(1999) cited factors which might

explain the overall low rate of HRT prescription in
postmenopausal women with ESRD. These researchers
suggested that physicians'

attitudes,

ethnicity,

secular

trends, and geographical location may have impacted the
prescribing patterns of these nephrology health care
providers. The current study's subjects in these
southeastern states were predominantly male

(80.77%) with

a general lack of knowledge regarding women's health as
evidenced by their response of uncertainty of dose to
prescribe H R T . While ethnicity or secular trends were not
identified in the current study, it is possible that the
southeastern geographical location could have influenced
these nephrology health care providers. Physician
liability was ranked as the number one reason for not
prescribing HRT. This factor either indicates true lack of
knowledge in regards to HRT or that HRT is viewed by the
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sample as an area for treatment solely ascribed to the
primary care provider. Another interpretation might be
that nephrology health care provider's are simply not
interested in women's health issues for they answered a
lack of interest in both continuing education units
related to HRT and no desire to possess an HRT pocket
guideline.

The need for increased knowledge may be masked

or denied by the provider as exhibited in Question 8 when
physician liability was chosen as the reason they would
not initiate HRT in their postmenopausal patients. This
answer may indicate that these nephrology health care
providers do lack the ability to assess, manage, and
evaluate the use of HRT. Providers also tended to
prescribe HRT only when they had to for surgically-induced
menopause and when patients ask for it were ranked as the
number one and two reasons to prescribe HRT by these
health care providers.
Conclusion
Nephrology health care providers identified
facilitators of HRT prescription as surgically-induced
menopause and the need for more research of HRT among
women with renal failure. Nephrology health care providers
ranked concern of liability as the number one barrier to
HRT prescription. Clearly the health care provider sample
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is not prevention care focused nor are they aware of
current positive research of benefits associated with HRT.
These findings and this researcher's position are neither
supported nor refuted in the literature.
Eleven

(42.31%) of the male health care providers

identified that 6 to 10% of their eligible postmenopausal
women were receiving HRT, while the 2 female health care
providers identified that > 50%

(7.6%) of their eligible

female patients were on HRT. This finding supports the
Health Promotion Model
factors,

(Pender,

1996) in that modifying

such as race, gender, or age, are factors that

directly impact health-promoting behaviors. This finding
also supports Gillen et al.
attitude, ethnicity,

(1999) who cited physician

secular trends, and geographical

location as factors, which might explain the overall low
prescription rate of HRT among women with renal failure.
The researcher recognized two potential limitations
that may have impacted study results: a potential sample
bias due to limited geographic setting and small sample
size and methodological concerns.
Implications for Nursing
Practice. The documented benefits of HRT have
significance for postmenopausal women with ESRD disease.
The younger age for entering menopause in this population
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of patients removes the protective cardiovascular,
cognitive,

and bone mass effects of estrogen. Women with

ESRD have a higher risk for cognitive dysfunction,
osteodystrophy,

accelerated atherosclerosis,

renal

and

cardiovascular disease compared to the general population.
Cardiovascular disease accounts for nearly half of the
mortality in dialysis patients each year. The potential
benefits of HRT for women with ESRD are numerous. The
cardiovascular protective effects alone could
significantly decrease related morbidity and mortality as
well as a substantial decrease in associated health care
costs

(Gipson,

1999). Nephrology health care providers are

in a unique position to initiate HRT as physicians and
nurse practitioners see dialysis patients on a weekly
basis. By viewing HRT as preventive medicine,

these health

care providers could dramatically impact related morbidity
and mortality in postmenopausal women with ESRD as well as
improve their quality of life by decreasing depression and
enhancing mood. Nurse practitioners'

are educated to

assess and treat the woman holistically. The nephrology
nurse practitioner could augment the care of the
nephrologist by initiating and monitoring with HRT and
providing teaching,

counseling,

and prevention reflecting

contraception, pregnancy, and menopause.
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Research. Advanced practice nurses in nephrology
should conduct more research regarding benefits of HRT
prescription to postmenopausal women with renal failure.
The current researcher clearly identified this need as it
was ranked as the number one external facilitator to HRT
initiation. The importance of publishing and presenting
this research at regional and national Nephrology meetings
is crucial.
Theorist. Pender's Health Promotion Model identifies
cognitive-perceptual factors that influence care providers
to initiate behaviors that are focused on health promotion
and disease prevention. Nephrology health care providers
clearly have ignored the use of HRT as both disease
prevention and health enhancing. The beliefs of nephrology
health care providers about primary prevention,
of health,

importance

and perceived benefits to health-promoting

behaviors are concepts from the Health Promotion Model
that are applicable to this study. Health care providers
working in nephrology must buy into the perceived benefits
of HRT. According to Pender, endorsing this concept would
make them more apt to refer, teach, counsel, and assess
their postmenopausal patients for signs of estrogen
deficiency. Another concept in the Health Promotion Model
is importance of health; if health care providers
recognized HRT as important to health, they would be more
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apt to prescribe.

If they support the benefits of HRT,

this can be either a facilitator or a barrier.
Recommendations
Based on the findings of this study, the following
recommendations were made:
Research
1. Replication of this study with a larger sample
including more women providers.
2. Replication of this study with an instrument which
has established validity and reliability.
3. Development of outcome measures for CEUs which has
a focus on HRT for all nephrology health care providers.
Nursing practice
1. Initiation of HRT as a primary prevention strategy
for postmenopausal women with renal failure by nephrology
nurse practitioners.
2. Avocation by Nurse Practitioners working in
nephrology for all female patients with ESRD to have
annual history and physical, which includes gynecological
surveillance.
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Tramel's Questionnaire
Please answer the following questions by filling in the blank or
placing a check (#/) by the appropriate answer.
1. Are you a
O a. MD
O

b. Board certified nephrologist

ni c. NP
In the state of (please check one)
O a . Alabama
0

b . Mississippi

01 c. Tennessee
If NP, please indicate clinical speciality area of NP preparation
and any additional certifications or specialty training in the
nephrology field.

Years practicing as a nephrology health care provider:
Gender
O a. Male
O
3.

b. Female

Please estimate the total number of patients you care for:
CÜ3 a. Less than 100

O

f. 501

to 600

O

101 to 200

O

g. 601

to 700

201 to 300

O

h. 701

to 800

b.

a c.
O

d. 301 to 400

i . More than 800

4.

Please estimate the number of female patients age 47 and older
whom you care for:____________________________________________

5.

Of these patients, what percent are on any form of estrogen
replacement?
O

a. 0

O b . 1 to 5%
O c.6 to 10%
O d.11 to 15%
O e.16 - 20%
O f-21 to 25%

01 g. 26 to 30%

O
O
O
O
O

h. 31 to 35%
i. 36 to 40%
j . 41 to 45%
k. 46 to 50%
1. More than 50%
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6.

Please approximate how many CEUs you
in the last year:
a. 0
□ e. 16 to 20
b. 1 to 5
□ f. 21 to 25
c . 6 to 10
g. 26 to 30
d. 11 to 15
h More than 31

O
O
C]

d
id .

Last 5 years :
LJ a. 0
b. 1 to 5
c. 6 to 10
d. 11 to 15

id e .16 to 20
d f. 21 to 25
d g. 26 to 30
d h. More than

d
d
d

31

For the following 3 questions, please rank in order of importance:
7.

Reasons you would initiate HRT in postmenopausal women under your
care :
_____ a. Relief of menopausal symptoms such as decreased libido,
depression, mood swings, and hot flashes.
_____ b. Prevention of osteoporosis
_____ c. Cardiovascular protective effects
_____ d. Patients ask for it
_____ e. Surgically-induced or premature menopause
f. Other.

8.

Comments:

Reasons you would not initiate HRT in postmenopausal women under
your care :
_____ a. View as primary care or as gyn specialty
_____ b. Physician liability; concerns with patient compliance
with follow-up care (pap smear)
_____ c. Concerns about adverse effects of HRT in your patients
_____ d. Client has preexisting cardiovascular disease.
_____ e. Unsure of what type and dose to prescribe
f. Other. Comments:

9.

What would make it easier or more convenient for you to prescribe
HRT?
__ a . CEUs
_____ b. Pocket Guide
_____ c. More research concerning benefits and or adverse
reactions in ESRD patients
_____ d. Journal articles
_____ e. Presentations at national/international meetings
f. Other. Comments:

10.

Please feel free to make any comments relevant to this research
study:
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Lynn Tramel
26 CR 403
Oxford, MS 38655

Dear Head Nurse or Charge Nurse,
I am a nephrology nurse of 18 years and a graduate student
at Mississippi University for Women. I am conducting a
research study about hormone replacement therapy (HRT) in
postmenopausal women with ESRD. I have found a limited
amount of research literature concerning benefits and or
specific risk factors in this population of patients.
I have enclosed 5 copies of a questionnaire concerning
HRT. Would you please give each nephrologist and or nurse
practitioner a packet?
If they would like to participate
in the study, please ask each one to fill out the
questionnaire and return it in the enclosed selfaddressed, stamped envelope. Return of the questionnaire
implies consent. Participation is voluntary, and
confidentiality will be maintained as no identifying names
will appear on the forms.
The majority of female patients are postmenopausal, and
this in itself has many health-related problems. These
problems compact the already complicated medical issues
that our patients must deal with on a daily basis. It is
my desire to research this area in hopes of improving the
quality of life for these women.
Thank you in advance for your time and participation;
coming from a hemodialysis background for many years, I
realize how busy you are and I am deeply grateful for your
assistance.
Sincerely,

Lynn Tramel
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Dear Head Nurse or Charge Nurse,
Just a friendly reminder about the questionnaire
concerning hormone replacement therapy in your
postmenopausal patients. Your input is much needed
and appreciated. If you have completed and returned
the questionnaire, thank you for your participation.
If you have not, please consider doing so.
Again, thank you in advance for taking the time to
participate in my study.
Sincerely,
Lynn Tramel
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26 CR 403
Oxford, MS 38655

Dear Nephrology Health Care Provider,
I am a nephrology nurse of 18 years and a graduate student
at Mississippi University for Women in Columbus,
Mississippi. I am conducting a research study about hormone
replacement therapy (HRT) in postmenopausal women with ESRD
and would like for you to participate in my study.
Enclosed please find a survey that I am using for my
research study. If you would like to participate, please
complete the questionnaire and return in the enclosed selfaddressed, stamped envelope. Return of the questionnaire
implies consent. Participation is voluntary, and
confidentiality will be maintained as no identifying names
will appear on the forms.
Thank you in advance for your time and participation;
coming from a hemodialysis background for many years, I
realize how busy you are, and I am deeply grateful for your
assistance.
Sincerely,

Lynn Trame1

